Clinical Trial Update: STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for STA-5312 administered on alternate weekdays every two weeks in patients with hematologic malignancies and solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Solid Tumors

Drugs mentioned

• STA-5312

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Hematological Malignancies, Leukemia | Phase 1 | Status: COMPLETED